Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Jenny

Clinical Cardiac Electrophysiology Mesa, AZ Medical Doctor

NPI 1629413828 CMS profile 4217222

6750 E Baywood Ave Ste 301, Mesa, AZ 85206

Open in the dashboard

General payments

$66,100

768 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Jenny of Mesa, AZ is reported in the CMS Open Payments database as having received $66,100 across 768 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,686 161
2024 General $12,256 184
2023 General $13,560 214
2022 General $10,042 114
2021 General $1,376 23
2020 General $6,897 28
2019 General $6,283 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Jenny
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Benjamin Jenny were reported at $15,686. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Benjamin Jenny Clinical Cardiac Electrophysiology median Middle half National median
2019 $6,283 $2,361 $585–$8,260 $163
2020 $6,897 $993 $247–$4,351 $114
2021 $1,376 $1,185 $326–$4,739 $132
2022 $10,042 $2,073 $554–$6,789 $149
2023 $13,560 $2,568 $759–$8,159 $160
2024 $12,256 $2,557 $703–$7,403 $164
2025 $15,686 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $16,298 100 payments
  2. Abbott Laboratories $14,854 159 payments
  3. Biosense Webster, Inc. $10,233 244 payments
  4. Impulse Dynamics (USA) Inc. $6,645 26 payments
  5. Cardiva Medical, Inc. $4,169 62 payments
  6. Biotronik Inc. $2,927 5 payments
  7. Atricure, Inc. $2,903 25 payments
  8. Medtronic Vascular, Inc. $2,411 34 payments
  9. Medtronic, Inc. $1,885 24 payments
  10. Medical Device Business Services, Inc. $1,091 4 payments
  11. Other $2,686 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $35,560 699 payments
  2. Travel and Lodging $14,237 57 payments
  3. Grant $8,750 2 payments
  4. Consulting Fee $7,154 7 payments
  5. Education $400 3 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $7,541 185 payments
  2. GENERAL - BRADY $5,000 1 payment
  3. ENSITE PRECISION $3,815 41 payments
  4. GENERAL BRADY $3,750 1 payment
  5. Cardiva VASCADE MVP VVCS 6-12F $3,429 45 payments
  6. Acticor 7 VR-T DX $2,727 2 payments
  7. BioMonitor $2,611 2 payments
  8. Edora 8 DR-T $2,596 1 payment
  9. Solia $2,596 1 payment
  10. Rivacor 7 DR-T $2,596 1 payment
  11. Other $35,208 493 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,049

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$698,047

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

44.9%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 475 $578,582
Xarelto Rivaroxaban Brand 53 $73,699
Multaq Dronedarone Hcl Brand 12 $23,947
Metoprolol Succinate Generic 335 $4,561
Clopidogrel Clopidogrel Bisulfate Brand 198 $2,441
Sotalol Sotalol Hcl Brand 112 $2,408
Amiodarone Hcl Generic 51 $2,035
Flecainide Acetate Generic 37 $1,476
Atorvastatin Calcium Generic 110 $1,268
Valsartan Generic 21 $942

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$474,930

Of which drugs: $793

Medicare patients

900

Average age 77

Services billed

5,816

392 women, 508 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 69%
Ischemic heart disease 57%
Arthritis 50%
Heart failure 41%
Diabetes 35%
Chronic kidney disease 35%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 38 152 $793

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

768 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record